RxDoctor Payments Data

Patricia Scheuerman, DO

Family Medicine · South Lyon, MINPI 1437474558

Payments from drug & device makers

$1,606in general payments, 2019–2025

Across 76 payments — averaging $21.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$485
  • Abbott$214
  • AbbVie$146
  • Lilly USA, LLC$140
  • Pfizer$90
  • Dexcom, Inc.$84
  • plus $447 from 13 others

What the payments were for

  • Food & beverage$1,606100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,606 in reported general payments places this provider in the 75th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$25,932
Medicare patients
157
Services billed
374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$21,305
MounjaroTirzepatide16$16,469
OzempicSemaglutide13$15,357
Emgality SyringeGalcanezumab-Gnlm11$7,451
Levothyroxine Sodium82$737
Atorvastatin Calcium96$686
Ventolin HfaAlbuterol Sulfate13$677
Albuterol Sulfate HfaAlbuterol Sulfate29$579
Memantine Hcl11$502
Losartan Potassium53$460
Ezetimibe11$455
Lisinopril62$390
Metoprolol Succinate15$379
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen25$371
Duloxetine Hcl18$357

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$48$21,30516 claims
Lilly USA, LLCMounjaro$140$16,46916 claims
Novo NordiskOzempic$485$15,35713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in South Lyon

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →